Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Patient access to medication. | Image Credit: Supatman - stock.adobe.com
Addressing Patent Hurdles, Payer Barriers, and Interchangeability

November 22nd 2024

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

Health care expenses. | Image Credit: izzuan - stock.adobe.com
Financial Incentives Drive Biosimilar Adoption in Japan

November 20th 2024

FDA logo and website | Image credit: Postmodern Studio - stock.adobe.com
FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges

November 6th 2024

Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD

October 30th 2024

health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com
Exploring the Complexities of Biosimilars and Interchangeability

October 30th 2024

Continuing Medical Education
View All
November 26th 2024

Managed Care Pharmacy: A Plan for the Future and How Pharmacists Are Leading the Way

0.5 Credits / General Pharmacy

More News

Saving Costs While Maintaining Quality of Care—The Value of Biosimilars in Oncology
November 8th 2018

Saving Costs While Maintaining Quality of Care—The Value of Biosimilars in Oncology

Surabhi Dangi-Garimella, PhD
According to a review published in Cancer Management and Research, biosimilar products present a viable cost-saving tool for providers participating in value-based care programs such as the Medicare Shared Savings Program or the Oncology Care Model.
This Week in Managed Care: October 26, 2018
October 26th 2018

This Week in Managed Care: October 26, 2018

This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.
AJMC® in the Press, October 12, 2018
October 12th 2018

AJMC® in the Press, October 12, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
PhRMA Tries to Use Opioid Bill to Shift Part D Costs to Medicare
September 21st 2018

PhRMA Tries to Use Opioid Bill to Shift Part D Costs to Medicare

Mary Caffrey
AARP and other groups reacted strongly to reports that the pharmaceutical industry was using efforts to combat the opioid crisis to roll back an agreement to close the coverage gap in Medicare Part D.
5 Actions Taken Since the Release of Trump's Drug Pricing Blueprint
August 31st 2018

5 Actions Taken Since the Release of Trump's Drug Pricing Blueprint

Samantha DiGrande
It’s been more than 100 days since President Trump and HHS Secretary Alex Azar announced the “American Patients First” drug pricing blueprint. Here are 5 actions the government has taken since its release.
Site Logo
August 22nd 2018

Clinical Updates, August 2018

Surabhi Dangi-Garimella, PhD Laura Joszt, MA Kelly Davio Samantha DiGrande
5 Things to Know About the FDA's Biosimilar Action Plan
August 10th 2018

5 Things to Know About the FDA's Biosimilar Action Plan

Kelly Davio
Since biosimilars gained a US approval pathway as part of the Affordable Care Act, these follow-on drugs have been widely seen as a key way to address the problem of high-cost biologic drugs. However, cost savings have been disappointing as only 12 biosimilar products have been approved to date, and just 4 have become commercially available. That’s a reality that led FDA Commissioner Scott Gottlieb, MD, to call the US market for biosimilars “anemic.”
What We're Reading: FDA's Biosimilar Plan; Philly Soda Tax Upheld; Health Subsidy Lawsuit Tossed
July 19th 2018

What We're Reading: FDA's Biosimilar Plan; Philly Soda Tax Upheld; Health Subsidy Lawsuit Tossed

AJMC Staff
FDA Commissioner Scott Gottlieb, MD, announced the release of the agency’s Biosimilar Action Plan; Philadelphia’s tax on soda and other sweetened beverages has been upheld by the Pennsylvania Supreme Court; a federal judge dismissed a lawsuit by 19 states against the Trump administration over the decision to end cost-sharing subsidies under the Affordable Care Act.
Site Logo
July 5th 2018

Improving Provider and Patient Acceptance of Biosimilars in Treating Cancer

https://www.pharmacytimes.org/on-demand/biosimilars-in-treating-cancer
Site Logo
June 26th 2018

The Complexities of Biosimilars and the Regulatory Approval Process

Steven Lucio, PharmD, BCPS
Site Logo
June 26th 2018

Opportunities and Challenges in Biosimilar Uptake in Oncology

Carina Dolan, PharmD, BCOP
5 Things to Know About the CREATES Act
June 22nd 2018

5 Things to Know About the CREATES Act

Kelly Davio
On June 14, 2018, the Senate Judiciary Committee voted 16 to 5 to report the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act to the Senate floor. Here are 5 key things to know about the proposed legislation.
AJMC® in the Press, June 1, 2018
June 1st 2018

AJMC® in the Press, June 1, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
5 Takeaways From the National Comprehensive Cancer Network's 23rd Annual Conference
March 30th 2018

5 Takeaways From the National Comprehensive Cancer Network's 23rd Annual Conference

Kelly Davio
The National Comprehensive Cancer Network (NCCN)’s 23rd Annual Conference, held March 22-24 in Orlando, Florida, brought together stakeholders from across the oncology landscape. Here are 5 key takeaways from the meeting.
Site Logo
March 23rd 2018

Managed Care Cast and Not So Different, the AJMC® Podcast Series, Give Experts a Forum

Both Managed Care Cast, from The American Journal of Managed Care®, and Not So Different, the podcast series from The Center for Biosimilars®, offer in-depth discussions of current healthcare issues.
Nine Physician Groups Oppose Proposed Drug Pricing Changes
March 14th 2018

Nine Physician Groups Oppose Proposed Drug Pricing Changes

Allison Inserro
Nine physician groups sent a letter to HHS Secretary Alex Azar Wednesday expressing concern about drug pricing proposals related to Medicare Part B and Medicare Part D that they said would hurt patient care.
This Week in Managed Care: March 9, 2018
March 9th 2018

This Week in Managed Care: March 9, 2018

This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs.
Drug Pricing Debate: Panel Talks About Transparency, Legislation
March 9th 2018

Drug Pricing Debate: Panel Talks About Transparency, Legislation

Allison Inserro
Does meaningful competition currently exist in the pharmaceutical industry and is there enough transparency on price? This was the crux of the discussion at the 2018 National Health Policy Conference of America’s Health Insurance Plans in Washington, DC.
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23rd 2018

5 Things to Know About Biosimilars and Inflammatory Bowel Disease

Kelly Davio
Last week, the European Crohn's and Colitis Organisation held its 13th annual congress in Vienna, Austria. At the meeting, researchers presented new data on using biosimilar anti–tumor necrosis factor therapies in treating Crohn disease and ulcerative colitis, 2 manifestations of inflammatory bowel disease. Here are 5 things to know about the research presented.
Site Logo
February 1st 2018

Biosimilars Update

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
This Week in Managed Care: January 12, 2018
January 12th 2018

This Week in Managed Care: January 12, 2018

This week, the top managed care stories included CMS unveiling a new voluntary bundled payment model; coverage from the JP Morgan Healthcare Conference, including immunotherapy's impact on HIV treatment and biosimilars; and news that 2 key diabetes devices will be covered by Medicare.
5 Things From the 36th Annual JP Morgan Healthcare Conference
January 12th 2018

5 Things From the 36th Annual JP Morgan Healthcare Conference

Kelly Davio
This week, the investors and analysts turned their attention to presentations by business leaders at the 36th Annual JP Morgan Healthcare Conference, held in San Francisco, California. Executives from the pharmaceutical and healthcare worlds showcased their products, pipelines, and visions for the future.
Express Scripts Is Built for the Future of Healthcare, Says CEO Wentworth
January 10th 2018

Express Scripts Is Built for the Future of Healthcare, Says CEO Wentworth

Laura Joszt, MA
It’s true, pharmacy benefit managers (PBMs) are complicated, admitted Tim Wentworth, president and CEO of Express Scripts, during his presentation at the JP Morgan Healthcare Conference in San Francisco, California. However, the company is built to succeed in the future of healthcare, he said.
Site Logo
December 20th 2017

AJMC®tv Interviews, December 2017

The Center for Biosimilars&reg Laura Joszt, MA
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
The Switch From Filgrastim to a Cheaper Alternative: Tbo-Filgrastim
December 1st 2017

The Switch From Filgrastim to a Cheaper Alternative: Tbo-Filgrastim

Jaime Rosenberg
With the increasing emergence of less expensive biologic alternatives, some health systems are making the switch. For a large healthcare system, the arrival of a cheaper alternative to filgrastim prompted the conversion to using tbo-filgrastim as the preferrred granulocyte-colony stimulating factor. The results were shared in a study published by the Journal of Managed Care & Specialty Pharmacy.
Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars
November 27th 2017

Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars

Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.
5 Things to Know About the Nocebo Effect and Biosimilars
November 24th 2017

5 Things to Know About the Nocebo Effect and Biosimilars

Kelly Davio
The “nocebo” effect, a phenomenon that occurs when a patient’s negative perception of a therapy causes a treatment to have a worse outcome than would otherwise be expected, has become a topic of increasing interest in the world of biosimilars as some patients begin to transition from familiar, high-cost biologics to new, lower-cost biosimilars.
5 Highlights From the 2017 ACR Meeting
November 11th 2017

5 Highlights From the 2017 ACR Meeting

Surabhi Dangi-Garimella, PhD
A review of some of the presentations at the American College of Rheumatology (ACR) 2017 Annual Meeting, in San Diego, California, where the discussions ranged from clinical progress witnessed in 2017 for the treatment of inflammatory conditions to reimbursement models in the rheumatology space.
Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business
November 8th 2017

Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business

Biosimilars for core therapeutics in cancer are starting to come out, and community oncologists need to understand what that means for their business, as well as what proposed policy changes could mean for reimbursement, explained Tesh Khullar,
In Debate Over Biosimilar Switching, Cost Is Key
November 6th 2017

In Debate Over Biosimilar Switching, Cost Is Key

Kelly Davio
Among the most anticipated sessions at the 2017 meeting of the American College of Rheumatology in San Diego, California was “The Great Debate: Biosimilars…to Switch, or Not to Switch? That Is the Question.”
<1
...
91011121314151617
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo